TERT and thyroid gland carcinoma: While RAS variants alone, regardless of the extent of variation, were associated with low-risk thyroid cancer in 88.8% of tumor samples, they did not definitively distinguish malignancy of an unknown tumor; however, detection of interpatient variabilities of RAS, BRAF, and TERT promoter variants in combination could assist in classifying indeterminate thyroid nodules.